A Reminder That No Drug Is Risk-Free
Article Abstract:
An advisory panel to the Food and Drug Administration found that the benefits of popular painkillers Vioxx, Celebrex and Bextra outweighed their heart disease risks, and that the drugs should not be prohibited but instead prescribed with caution.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Product standards, safety, & recalls, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Company legal issue, Product defects and recalls, Investigations, Complications and side effects, Analgesics, Celebrex (Medication), Vioxx (Medication), Merck & Company Inc., Bextra (Medication)
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Panel Backs Drug Amid Conflict Concerns
Article Abstract:
The Food and Drug Administration decided to approve Bristol-Myers Squibb's diabetes drug Pargluva and Sanofi-Aventis' and Pfizer's diabetes drug Exubera in spite of public concerns about conflicts of interests.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Product development, France, Alliances, partnerships, Drug therapy, Diabetes, Diabetes mellitus, Beliefs, opinions and attitudes, Conflict of interests (Public office), Conflicts of interest (Public office), Bristol-Myers Squibb Co., BMY, Cooperative agreement for product development, Alliances and partnerships, SNY, Sanofi-Aventis S.A., Plutzky, Jorge, Pargluva (Medication), Exubera (Medication)
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Laws, regulations and rules, Pharmaceutical industry, Government regulation, Ethical aspects, Pfizer Inc., Licensing, certification and accreditation, PFE, United States. Food and Drug Administration
Similar abstracts:
- Abstracts: Many Are Surprised By Bold Decisions Of the Bush F.D.A. Bre-X affiliate to change name, seek financing
- Abstracts: New York Magazine Sold for $55 Million To Wall St. Figure. Wall Street Wondering What's Up In Cable Deal
- Abstracts: What's second prize?: A reality check on what the 'The Apprentice' winners won. Phillip of Macedon: A Victorian winery is producing cutting-edge pinot noir and chardonnay from Australia's edgiest wine region
- Abstracts: Wild about the boy. A miner miracle. Three (more) years of hard labor
- Abstracts: Banknorth sets stage for TD's rapid US expansion: TD a bigger catch if deals allowed here. Bay St. takes heart as hiring resumes: MBA recruitment drives signal financial sector ending two-year hiring freeze
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.